PE20151591A1 - Sal de abexinostato novedosa, forma cristalina relacionada, metodo de preparacion de esta y las composiciones farmaceuticas que la contienen - Google Patents

Sal de abexinostato novedosa, forma cristalina relacionada, metodo de preparacion de esta y las composiciones farmaceuticas que la contienen

Info

Publication number
PE20151591A1
PE20151591A1 PE2015001875A PE2015001875A PE20151591A1 PE 20151591 A1 PE20151591 A1 PE 20151591A1 PE 2015001875 A PE2015001875 A PE 2015001875A PE 2015001875 A PE2015001875 A PE 2015001875A PE 20151591 A1 PE20151591 A1 PE 20151591A1
Authority
PE
Peru
Prior art keywords
crystalline form
abexinostate
novedosa
salt
preparation
Prior art date
Application number
PE2015001875A
Other languages
English (en)
Inventor
Anne Pimont-Garro
Philippe Letellier
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48521256&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151591(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of PE20151591A1 publication Critical patent/PE20151591A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups

Abstract

Se refiere a tosilato abexinostato de la Formula (II), y la forma l cristalina de este caracterizado por el patron de difraccion X en polvo del mismo, el espectro de Raman de este, y el espectro de NMR CP/MAS 13C en estado solido. La forma I cristalina de tosilato de abexinostato esta destinada para el tratamiento contra el cancer, mas particularmente para el tratamiento de un carcinoma, un tumor, un neoplasma, un linfoma, un melanoma, un glioma, un sarcoma o un blastoma. Esta forma cristalina es especialmente valiosa en un contexto industrial en vista de su baja higroscopicidad
PE2015001875A 2013-03-04 2014-03-03 Sal de abexinostato novedosa, forma cristalina relacionada, metodo de preparacion de esta y las composiciones farmaceuticas que la contienen PE20151591A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772191P 2013-03-04 2013-03-04
FR1351898A FR3002733B1 (fr) 2013-03-04 2013-03-04 Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
PE20151591A1 true PE20151591A1 (es) 2015-11-06

Family

ID=48521256

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001875A PE20151591A1 (es) 2013-03-04 2014-03-03 Sal de abexinostato novedosa, forma cristalina relacionada, metodo de preparacion de esta y las composiciones farmaceuticas que la contienen

Country Status (39)

Country Link
US (3) US9115108B2 (es)
EP (2) EP2964622B1 (es)
JP (2) JP6449177B2 (es)
CN (2) CN109734690B (es)
AR (1) AR094935A1 (es)
AU (2) AU2014224456B2 (es)
BR (1) BR112015021443A2 (es)
CA (1) CA2903369C (es)
CL (1) CL2015002488A1 (es)
CR (1) CR20150456A (es)
CY (1) CY1119147T1 (es)
DK (1) DK2964622T3 (es)
DO (1) DOP2015000215A (es)
EA (2) EA030689B1 (es)
ES (1) ES2632471T3 (es)
FR (1) FR3002733B1 (es)
GE (1) GEP201706760B (es)
HK (1) HK1220965A1 (es)
HR (1) HRP20171041T1 (es)
HU (1) HUE035299T2 (es)
IL (1) IL241038B (es)
JO (1) JO3402B1 (es)
LT (1) LT2964622T (es)
MA (1) MA38423B1 (es)
ME (1) ME02814B (es)
MX (1) MX355436B (es)
MY (1) MY192027A (es)
NI (1) NI201500122A (es)
PE (1) PE20151591A1 (es)
PL (1) PL2964622T3 (es)
PT (1) PT2964622T (es)
RS (1) RS56224B1 (es)
SG (1) SG11201506952YA (es)
SI (1) SI2964622T1 (es)
TN (1) TN2015000367A1 (es)
TW (1) TWI506023B (es)
UA (1) UA118550C2 (es)
UY (1) UY35356A (es)
WO (1) WO2014135776A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153514A2 (en) 2010-06-03 2011-12-08 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
JP6575950B2 (ja) 2012-07-24 2019-09-18 ファーマサイクリックス エルエルシー Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
JP6178861B2 (ja) 2012-11-02 2017-08-09 ファイザー・インク ブルトン型チロシンキナーゼ阻害剤
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
FR3025197B1 (fr) * 2014-09-03 2019-09-06 Pharmacyclics, Inc. Nouveau sel de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3025196B1 (fr) * 2014-09-03 2019-09-06 Pharmacyclics, Inc. Nouveaux sels de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2960044A1 (en) * 2014-09-03 2016-03-10 Pharmacyclics Llc Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
WO2017011314A1 (en) * 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
WO2022261401A1 (en) 2021-06-10 2022-12-15 Teva Pharmaceuticals International Gmbh Solid state forms of abexinostat and process for preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) * 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
GB0020721D0 (en) * 2000-08-22 2000-10-11 Merck Sharp & Dohme Therapeutic agents
BRPI0409227C1 (pt) * 2003-04-07 2021-05-25 Axys Pharm Inc composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
US8609854B2 (en) * 2009-09-24 2013-12-17 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
WO2013039956A2 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating mood disorders
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PT2964622T (pt) 2017-07-13
FR3002733B1 (fr) 2015-08-14
CN109734690B (zh) 2023-08-11
UA118550C2 (uk) 2019-02-11
DK2964622T3 (en) 2017-07-31
GEP201706760B (en) 2017-10-25
AU2014224456A8 (en) 2015-10-22
CA2903369A1 (en) 2014-09-12
US10150748B2 (en) 2018-12-11
EP2964622A1 (fr) 2016-01-13
US20140249215A1 (en) 2014-09-04
JP6720280B2 (ja) 2020-07-08
EA030689B1 (ru) 2018-09-28
DOP2015000215A (es) 2015-09-30
SG11201506952YA (en) 2015-10-29
TN2015000367A1 (fr) 2017-01-03
MX355436B (es) 2018-04-18
CN105263917B (zh) 2018-11-20
EP2964622B1 (fr) 2017-04-19
JO3402B1 (ar) 2019-10-20
HRP20171041T1 (hr) 2017-10-06
WO2014135776A1 (fr) 2014-09-12
JP6449177B2 (ja) 2019-01-09
AR094935A1 (es) 2015-09-09
FR3002733A1 (fr) 2014-09-05
UY35356A (es) 2014-09-30
EP3252044A1 (fr) 2017-12-06
ME02814B (me) 2018-01-20
BR112015021443A2 (pt) 2017-07-18
AU2014224456A1 (en) 2015-10-08
CN105263917A (zh) 2016-01-20
TW201434822A (zh) 2014-09-16
US9115108B2 (en) 2015-08-25
JP2019069955A (ja) 2019-05-09
CL2015002488A1 (es) 2016-03-11
NI201500122A (es) 2018-10-18
RS56224B1 (sr) 2017-11-30
US20170313671A1 (en) 2017-11-02
AU2014224456B2 (en) 2018-01-25
CY1119147T1 (el) 2018-02-14
NZ712380A (en) 2020-10-30
SI2964622T1 (sl) 2017-10-30
AU2018202881A1 (en) 2018-05-17
PL2964622T3 (pl) 2017-10-31
EA201591530A1 (ru) 2016-01-29
MX2015011566A (es) 2016-06-24
ES2632471T3 (es) 2017-09-13
US20150315167A1 (en) 2015-11-05
MA38423B1 (fr) 2017-10-31
JP2016510735A (ja) 2016-04-11
HK1220965A1 (zh) 2017-05-19
HUE035299T2 (en) 2018-05-02
EA201891023A1 (ru) 2019-03-29
AU2018202881B2 (en) 2020-02-27
LT2964622T (lt) 2017-08-10
EA039113B1 (ru) 2021-12-06
CA2903369C (en) 2021-06-08
IL241038B (en) 2019-09-26
IL241038A0 (en) 2015-11-30
TWI506023B (zh) 2015-11-01
MY192027A (en) 2022-07-23
MA38423A1 (fr) 2017-02-28
CN109734690A (zh) 2019-05-10
CR20150456A (es) 2015-10-21

Similar Documents

Publication Publication Date Title
PE20151591A1 (es) Sal de abexinostato novedosa, forma cristalina relacionada, metodo de preparacion de esta y las composiciones farmaceuticas que la contienen
CY1122222T1 (el) Συνθεση βορονικων αλατων και χρησεις αυτων
GT201600123A (es) Inhibidores de syk
MX2018015094A (es) Derivados de carbonucleosidos sustituidos utiles como agentes antineoplasicos.
CU20160120A7 (es) Benzimidazol-2-aminas como inhibidores de midh1
CL2016003350A1 (es) Inhibidores de demetilasa-1 especifica de lisina
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
CR20150633A (es) Derivados del bipirazol como inhibidores jak
MA40076A (fr) Inhibiteurs de syk
NI201800042A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
MX2018005725A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer.
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
AR094964A1 (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd)
UY33547A (es) COMPUESTOS QUÍMICOS Bcl-2 y Bcl-XL
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
EA034822B9 (ru) Производные n-пиридинилацетамида в качестве ингибиторов сигнального пути wnt
CR20150245A (es) Proceso novedoso para la elaboración de compuestos para uso en el tratamiento de cáncer
MX2016008259A (es) Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa.
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv
CO2017000011A2 (es) Derivados de quinolizinona como inhibidores de pi3k
MX2018006953A (es) Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer.
PL410329A1 (pl) Kompleksy rutenu, sposób ich wytwarzania oraz ich zastosowanie
DOP2015000299A (es) Derivados de prodroga de triazolpiridinas sustituidas